Interstitial lung diseases (ILDs) encompass a heterogeneous group of disorders characterized by various forms of interstitial lung damage. They present significant diagnostic and therapeutic challenges for clinicians due to their diverse etiologies and clinical presentations.
ILDs are classified based on etiology into idiopathic, related to systemic diseases, or due to environmental exposures. The most common idiopathic ILD is idiopathic pulmonary fibrosis (IPF), characterized by a usual interstitial pneumonia pattern on histology. Connective tissue diseases such as rheumatoid arthritis or systemic sclerosis can also cause ILDs. Environmental factors like exposure to asbestos or silica can lead to pneumoconiosis.
Patients typically present with progressive dyspnea and nonproductive cough. Physical examination may reveal crackles and finger clubbing. Diagnosis is often challenging, requiring a combination of clinical, radiological, and histopathological findings. High-resolution computed tomography (HRCT) is the imaging modality of choice, often revealing characteristic patterns. Lung biopsy may be necessary in certain cases.
Treatment of ILDs is largely based on the underlying cause. For IPF, antifibrotic agents such as pirfenidone and nintedanib are recommended. In ILDs associated with connective tissue diseases, immunosuppressive therapy is often beneficial. Lung transplantation may be considered in advanced cases.
The prognosis of ILDs varies widely, depending on the specific diagnosis. IPF has a poor prognosis with a median survival of 2-3 years post-diagnosis. In contrast, ILDs due to connective tissue diseases have a more variable course and may have a better prognosis with appropriate treatment.
ILDs are a complex group of disorders requiring a comprehensive and multidisciplinary approach for optimal management. Continued research efforts are essential to enhance our understanding of these diseases and develop more effective therapeutic strategies.
1.
Combo Therapy Boosts Early CML Response but Not Long Term
2.
PNH With Extravascular Hemolysis Approves Factor D Inhibitor.
3.
In a long-term comparison with adjuvant RT, salvage radiotherapy after prostateectomy is the most successful treatment.
4.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
5.
Classifying childhood brain cancers by immune response may improve diagnostics and treatments
1.
Precision Oncology: Integrating Genomics and Data to Shape Cancer Care’s Future
2.
Decoding Hamartomas: Understanding Their Causes and Symptoms
3.
Understanding the Silent Threat: Unveiling Prostate Cancer Symptoms
4.
Battling Blood Cancers: Advances in HIV-Related Hematologic Malignancies in the ART Era
5.
Breaking Barriers: Innovative Approaches in Brain Tumor Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
2.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
3.
Efficient Management of First line ALK-rearranged NSCLC
4.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation